DENOVA评分预测粪肠球菌菌血症感染性心内膜炎的外部验证
本研究为前瞻性多中心队列(2019-2024年,23中心6国,543例成人单微生物粪肠球菌菌血症),外部验证DENOVA评分对感染性心内膜炎的预测效能。结果显示,连续变量AUC 0.871(95%CI 0.835-0.906),阈值≥3时敏感度79.2%、特异度83.0%,决策曲线分析示多数阈值概率下净临床获益,减少不必要的经食管超声。
要点
- DENOVA评分在粪肠球菌菌血症患者中预测感染性心内膜炎的AUC为0.871。
- 阈值≥3时敏感度79.2%、特异度83.0%。
- 决策曲线分析示DENOVA≥3可减少不必要的经食管超声。
核心结论
- DENOVA评分支持粪肠球菌菌血症患者感染性心内膜炎的风险分层,指导临床决策与经食管超声使用。
研究设计与样本
- 前瞻性多中心队列研究(2019-2024年),23个中心,6个国家(意大利、西班牙、以色列、巴西、瑞士、罗马尼亚),纳入543例成人单微生物粪肠球菌菌血症且至少接受一次超声心动图评估的患者。
主要发现
- 543例中125例(23.0%)诊断为感染性心内膜炎。
- DENOVA评分作为连续变量时AUC为0.871(95%CI 0.835-0.906)。
- 预设阈值DENOVA≥3时,敏感度79.2%(95%CI 71.0-85.9),特异度83.0%(95%CI 79.1-86.5)。
- 决策曲线分析显示DENOVA≥3在大多数阈值概率下与正的净临床获益相关,并减少不必要的经食管超声心动图。
关键数值与推荐
- 感染性心内膜炎诊断依据2023年Duke标准。
- DENOVA评分连续变量AUC 0.871(95%CI 0.835-0.906)。
- DENOVA≥3时敏感度79.2%(95%CI 71.0-85.9),特异度83.0%(95%CI 79.1-86.5)。
临床怎么用
- 对粪肠球菌菌血症患者可使用DENOVA评分进行感染性心内膜炎风险分层,评分≥3时提示需进一步评估,并可能指导经食管超声心动图的合理使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The DENOVA score was developed to support risk stratification for infective endocarditis (IE) in patients with Enterococcus faecalis bacteremia (EfB) and to guide echocardiographic evaluation; external validation remains, however, limited. The objective of this study was to externally validate the DENOVA score in a large prospective international cohort of patients with EfB. METHODS: Prospective multicentre cohort study (2019-2024) conducted across 23 centres in six countries (Italy, Spain, Israel, Brazil, Switzerland, and Romania), including adult patients with monomicrobial EfB who underwent at least one echocardiographic evaluation as part of the study protocol. Definite IE was defined according to the 2023 Duke criteria. The DENOVA score was externally validated; discrimination was assessed by the area under the receiver operating characteristic curve, calibration by observed versus predicted risk plots, and clinical utility by decision curve analysis at the predefined threshold (DENOVA ≥3). Performance of the NOVA score was evaluated as a secondary analysis. RESULTS: Among 543 patients, 125 (23.0%) were diagnosed with IE. When evaluated as a continuous variable, the DENOVA score showed an area under the receiver operating characteristic curve of 0.871 (95% CI 0.835-0.906). At the predefined threshold (DENOVA ≥3), sensitivity was 79.2% (95% CI 71.0-85.9) and specificity was 83.0% (95% CI 79.1-86.5). Decision curve analysis showed that DENOVA ≥3 was associated with positive net clinical benefit across most threshold probabilities, with a reduction in unnecessary transoesophageal echocardiographies. CONCLUSIONS: The study demonstrated that DENOVA supports risk stratification for IE in patients with EfB, informing clinical decision-making and use of transoesophageal echocardiography.
引用
- Varisco B, Piovani D, Del Turco ER, et al. Clinical utility of the DENOVA score for predicting infective endocarditis in Enterococcus faecalis bacteraemia: external validation with decision curve analysis. Clin Microbiol Infect. 2026. PMID: 41748017. doi:10.1016/j.cmi.2026.02.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。